Treatment of hot flashes in women with a previous diagnosis of breast cancer;Traitement des bouffées de chaleur associées au cancer du sein

Bulletin du Cancer

Volumn 91, Issue 4, 2004, Pages 339-349

  Debourdeau, Philippe ^a   Bachelot, Thomas ^b   Zammit, Christine ^c   Aletti, Marc ^a   Gallineau, Cyrille ^a   Gligorov, Joseph ^d  

^a HIA Desgenettes   (France)

^b CENTRE LÉON BÉRARD   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d HÔPITAL TENON   (France)

Author keywords

Breast cancer; Hot flashe; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; CLONIDINE; CONJUGATED ESTROGEN; DAIDZEIN; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; FLUOXETINE; GABAPENTIN; GENISTEIN; GESTAGEN; ISOFLAVONE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PAROXETINE; PHYTOESTROGEN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; VERALIPRIDE;

ADJUVANT CHEMOTHERAPY; ANAMNESIS; ANOREXIA; BEHAVIOR DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DAILY LIFE ACTIVITY; DRUG ERUPTION; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; NAUSEA; REVIEW; SLEEP DISORDER; SOMNOLENCE; TUMOR PROMOTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIETARY SUPPLEMENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MEDICAL HISTORY TAKING; MIDDLE AGED; PROGESTINS; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 2442652569     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGtath P et al. Hot flashes in post menopausal women treated for breast carcinoma : prevalence, severity, correlates, management and relation to quality of life. Cancer 1998 ; 82 : 1682-91.
2. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with an history of breast cancer and attitude toward oestrogen replacement therapy. J Clin Oncol 1995 ; 13 : 2737-44.
3. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998 ; 152 : 396-411.
4. McPhail G, Smith LN. Acute menopause symptoms during adjuvant systemic treatment for breast cancer. Cancer Nurs 2000 ; 23 : 430-43.
5. Lower EE, Blau R, Gazder P, Tumala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Women's Health Gend Based Med 1999 ; 8 : 949-54.
6. Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999 ; 26 : 1311-7.
7. Loprinzi CL, Zahasky K, Sloan J, Novotny PJ, Quella SK. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000 ; 1 : 52-6.
8. Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms functioning and quality of life. J Natl Cancer Inst Monogr 2001 ; 30 : 130-4.
9. Love RR, Cameron L, Conelli BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991 ; 151 : 1842-7.
10. Oldenhave A, Jaszmann LJB. The climacteric : absence or presence of hot flushes and their relation to other complaints. Prog Basic Clin Pharmacol 1991 ; 6 : 6-39.
11. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002 ; 77 : 1207-18.
12. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes DF. Hot flushes. Lancet 2002 ; 360 : 1851-61.
13. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definition of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998 ; 16 : 327-33.
14. Fellowes D, Fallowfielde L, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer : how informative are documented symptom profiles in medical notes for "well-tolerated" treatments ? Breast Cancer Res Treat 2001 ; 66 : 73-81.
15. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001 ; 19 : 4280-90.
16. Carpenter JS. The hot flash related daily interference scale : a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001 ; 22 : 979-89.
17. Carpenter JS, Wells N, Lambert B, Watson P, Slayton T, Chak B et al. A pilot study of magnetic therapy for hot flashes after breast cancer. Cancer Nursing 2002 ; 25 : 104-9.
18. Towlerton G, Filshie J. Acupuncture in the control of vasomotor symptoms caused by tamoxifen. Palliat Med 1999 ; 13 : 445.
19. David A, Don R, Tajchner G, Weissglas L. Veralipride : alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988 ; 158 : 1107-15.
20. Barton D, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998 ; 16 : 495-500.
21. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D et al. Randomized trial of black cohosh for treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001 ; 19 : 2739-45.
22. Oddens BJ. The climacteric cross-culturally : the International Health Foundation South-East Asia study. Maturitas 1994 ; 19 : 155-6.
23. Maudelonde T, This P. Utilisation de phyto-estrogènes après cancer du sein. Gynecol Obstet Fertil 2003 ; 31 : 667-75.
24. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, La Vasseur BI et al. Evaluation of soy phytoestrogens for treatment of hot flashes in breast cancer survivors : a north central cancer treatment group trial. J Clin Oncol 2000 ; 18 : 1068-74.
25. Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer : a randomised, controlled clinical trial. J Clin Oncol 2002 ; 20 : 1449-55.
26. Laufer LR, Erlik Y, Meldrum D, Judd HL. Effect of clonidine on hot flashes in post menopausal women. Obstet Gynecol 1982 ; 60 : 583-6.
27. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Maillard JA et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994 ; 12 : 155-8.
28. Pandya KJ, Raubettas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes : a university of Rochester Cancer Community Clinical Oncology program study. Ann Intern Med 2000 ; 132 : 788-93.
29. Guttuso T, Kurlan R, Mc Dermont M, Kieburtz K. Gabapentin's effect on hot flashes in post menopausal women : a randomized controlled trial. Obstet Gynecol 2003 ; 101 : 337-45.
30. Weitzer MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002 ; 23 : 337-45.
31. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000 ; 11 : 17-22.
32. Loprinzi CL, Pisansky M, Fonseca R, Sloan JA, Zahasky KM, Quella SK et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flahes in cancer survivors. J Clin Oncol 1998 ; 16 : 2377-81.
33. Loprinzi CL, Krugler JW, Sloan JA, Mailliard JA, La Vasseur BI, Barton DL et al. Venlafaxine in the management of flashes in survivors of breast cancer : a randomised controlled trial. Lancet 2000 ; 356 : 2059-63.
34. Barton DL, La Vasseur B, Loprinzi C, Novotny P, Wilwerding MB, Sloan J. Venlafaxine for the control of hot flashes : results of a longitudinal continuation study. Oncol Nurs Forum 2002 ; 29 : 33-9.
35. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA et al. Phase III evaluation of fluoxetine for rreatment of hot flashes. J Clin Oncol 2002 ; 20 : 1578-83.
36. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss H, Fores W. Randomized, placebo-controlled study of sertraline (Zoloft™) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. J Clin Oncol 2001 ; 20 : 397a (abstract 1585).
37. Barton DL, Loprinzi CL, Sloan JA, Dakhil SR, Collins ML, Martin LS et al. Pilot evaluations of newer antidepressants for hot flashes. J Clin Oncol 2002 ; 21 : 362a (abstract 1463).
38. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA et al. Megestrol acetate for prevention of hot flashes. N Engl J Med 1994 ; 331 : 347-52.
39. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T et al. Long term use of megestrol acetate by cancer survivors for treatment of hot flashes. Cancer 1998 ; 82 : 1784-8.
40. Bertelli G, Venturini M, De ML, Constantini M, Bergaglio M, Pastounos L. Depot intramuscular medroxyprogesterone acetate (MPA) vs oral megestrol acetate (MA) for the treatment of hot flashes in breast cancer survivors : results of GONO (Gruppo Oncologico Nord Ovest) MIG-4 phase II trial. J Clin Oncol 1999 ; 18 : 592a (abstract 2286).
41. Benghiat A, Cassidy SA, Davidson HE, Mancero FS, Pickard JG, Tyrrell CJ. Megestrol acetate in the treatment of advanced post-menopausal breast cancer. Eur J Surg Oncol 1986 ; 12 : 43-5.
42. Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 1991 ; 11 : 5032-43.
43. Manson JE, Martin KA. Post menopausal hormone replacement therapy. N Engl J Med 2001 ; 345 : 34-40.
44. Pritchard KI. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and review of possible alternatives. Ann Oncol 2001 ; 12 : 301-10.
45. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6,8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002 ; 288 : 49-57.
46. Hemmminiki E, McPherson K. Impact of post-menopausal hormone therapy on cardiovascular events and cancer : pooled data from clinical trials. Br Med J 1997 ; 315 : 149-53.
47. WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002 ; 288 : 221-33.
48. Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes. Aetiology and management. Drugs and Aging 2001 ; 18 : 597-606.
49. Eden JA. Estrogen replacement therapy in survivors of breast cancer. Drug and Aging 1996 ; 8 : 127-33.
50. Vassilopoulou-Sellin R, Klein MJ. Estrogen replacement therapy after treatment for localized breast carcinoma. Cancer 1996 ; 78 : 1043-8.
51. Ganz PA, Greendale GA, Kahn B, O'Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy ? Cancer 1999 ; 86 : 14-20.
52. Treatment of oestrogen deficiency symptoms in women surviving breast cancer. Part 6 : Executive summary and consensus statement. Proceedings of a conference held Board's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology 1999 ; 13 : 859-75.
53. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993 ; 165 : 372-5.
54. Powles TJ, Hickish T, Casey S, O'Brien M. Hormone replacement therapy after breast cancer. Lancet 1993 ; 342 ; 60-1.
55. DiSaia PJ, Grosen EA, Odicino F, Cowan B, Pecorelli S, Wile AG et al. Replacement therapy for breast cancer survivors. Cancer 1995 ; 76 : 2075-8.
56. Peters GN, Jones SE. Estrogen replacement therapy in breast cancer patients : a time for change. J Clin Oncol 1996 ; 15 : 121 (abstract 148).
57. Decket D, Cox T, Burdakin J, Jaiyesimi I, Pettinga J, Benitez P. Hormone replacement therapy in breast cancer survivors. J Clin Oncol 1996 ; 15 : 136 (abstract 209).
58. Espie M, Gotins A, Perret F, Tournant B, Lipszyg J, Nowak H et al. Hormone replacement therapy in patients treated for breast cancer : analysis of a cohort of 120 patients. J Clin Oncol 1999 ; 18 : 586a (abstract 592).
59. Bluming AZ, Waisman JR, Dosik GM. Hormone replacement therapy in women with previously treated primary breast cancer : update VIII. J Clin Oncol 2002 ; 21 : 65a (abstract 259).
60. Dew J, Eden J, Beller E, Magarey C, Scwartz P, Crea P et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998 ; 1 : 137-42.
61. Eden JA, Bush T, Nand S Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of cancer. Menopause 1995 ; 2 : 67-72.
62. Beckmann MW, Mohrmann T, Kuschel B. Hormonersatz-Therapie (HRT) nach Mammakarzinomerkrankung-ergebnisse einer Beobachtungsstudie. Gerburtsh u Frauenheilk 1998 ; 58 : 193-6.
63. Ursic-Vrscaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999 ; 25 : 146-51.
64. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, McNeese M, Singletary SE, Theriault RL. Estrogen replacement therapy after localized breast cancer : clinical outcome of 319 women followed prospectively. J Clin Oncol 1999 ; 17 : 1482-7.
65. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation with recurrence and mortality. J Natl Cancer Inst 2001 ; 93 : 754-62.
66. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer : a systematic review and quantitative assessment of risk. J Clin Oncol 2001 ; 19 : 1357-63.
67. Pritchard KI, Khan H, Levine M for the steering committee on clinical practice guidelines for the care and treatment of breast cancer. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. Can Med Asso J 2002 ; 16 : 1017-22.